HRT Risks: Breast Cancer, Clots, and Stroke

Almost everything most women think they know about hormone therapy risk comes from a single July 2002 press conference — and most of it was wrong, or at least wildly oversimplified. The Women's Health Initiative (WHI) investigators halted the combined estrogen-plus-progestin arm of their trial early, announced a "26% increase in breast cancer," and set off a panic that caused millions of women to throw their patches in the trash overnight. Prescriptions for HRT in the United States fell by more than half within two years. What almost nobody reported at the time was the absolute number: 8 extra breast cancer cases per 10,000 women per year. That is smaller than the excess breast-cancer risk from drinking two glasses of wine a night.

This page walks through what modern re-analysis of the WHI data actually shows, how risk varies enormously depending on when you start HRT, what kind of estrogen you take, and how you deliver it. It also covers who truly should not take HRT. The goal is not to minimize risk — blood clots and strokes are real and can kill — but to give you numbers you can compare to the risks you already accept every day.

Table of Contents

  1. The 2002 WHI Story — and What Went Wrong With the Headlines
  2. The Timing Hypothesis: Age at Initiation Matters Enormously
  3. The Estrogen-Alone Surprise
  4. Blood Clots (VTE): Route of Delivery Changes Everything
  5. Stroke Risk: Oral Estrogen, Age, and Baseline Risk
  6. Which Progestogen? Micronized Progesterone vs MPA
  7. Absolute Contraindications — Who Should Not Take HRT
  8. Personalizing Your Risk: Gail, Family History, BRCA
  9. Putting HRT Risk in Everyday Terms
  10. Key Research Papers
  11. PubMed Topic Searches
  12. Connections

The 2002 WHI Story — and What Went Wrong With the Headlines

The Women's Health Initiative was the largest randomized trial ever run in menopausal women — more than 27,000 participants across two arms. The estrogen-plus-progestin arm used conjugated equine estrogens (CEE, Premarin) 0.625 mg daily plus medroxyprogesterone acetate (MPA, Provera) 2.5 mg daily. The average participant was 63 years old at enrollment — more than a decade past the average age of menopause.

On July 9, 2002, the data safety monitoring board stopped the trial after 5.2 years. The headline number: a hazard ratio of 1.26 for invasive breast cancer — a "26% increase." What that actually meant in absolute terms:

Stated that way, the number is real but small. For comparison: the excess breast-cancer risk from drinking one alcoholic drink per day is roughly 7–10 extra cases per 10,000 women-years. The excess risk from a BMI over 30 is larger still. The story that got told in 2002 — "HRT causes breast cancer" — conflated a modest absolute increase in one specific regimen (oral CEE + oral MPA, started at an average age of 63) with all hormone therapy in all women.

There were also increases in coronary heart disease events and stroke in that arm, plus increased VTE — all real, all in older women started late, all using oral conjugated equine estrogens and a synthetic progestin that modern prescribers rarely use anymore.

The Timing Hypothesis: Age at Initiation Matters Enormously

The long-term follow-up analysis published by JoAnn Manson and colleagues in JAMA in 2017 tracked WHI participants for 18 years. When results were broken down by age at initiation, the picture changed dramatically:

This is the "timing hypothesis" or "window of opportunity." It is now accepted by the North American Menopause Society (now The Menopause Society), the Endocrine Society, the International Menopause Society, and the British Menopause Society. Their consensus: for symptomatic women under 60 and within 10 years of menopause, the benefits of HRT generally outweigh the risks. After 60 or beyond 10 years, the calculation tilts less favorably, and the decision becomes much more individual.

The Estrogen-Alone Surprise

The WHI ran a second arm for women who had already had a hysterectomy, so they did not need a progestogen to protect the uterine lining. These 10,739 women received CEE 0.625 mg daily alone or placebo. The results, published and updated through 2020:

This finding, almost never reported in the mainstream press, strongly suggests that the synthetic progestin MPA — not estrogen itself — drove most of the breast-cancer signal in the combined arm. Estrogen without MPA, in hysterectomy women, actually appears breast-protective.

Whether that protection extends to women who still have a uterus and must take some progestogen is the central question of modern HRT practice. The answer depends heavily on which progestogen you choose — see section 6 below.

Blood Clots (VTE): Route of Delivery Changes Everything

Venous thromboembolism (VTE) — deep vein thrombosis and pulmonary embolism — is the most clear-cut risk of systemic HRT. But it is almost entirely a risk of oral estrogen, not transdermal.

Here is why. When you swallow an estrogen pill, the hormone is absorbed through the gut and travels through the portal vein directly to the liver in high concentration. The liver responds by upregulating production of clotting factors (fibrinogen, factor VII, factor X) and down-regulating anticoagulants (antithrombin, protein S). A patch or gel delivers estrogen through the skin into the general circulation, so the liver only sees physiologic bloodstream concentrations — not a concentrated first-pass hit.

The ESTHER case-control study (Canonico et al., 2007) and subsequent meta-analyses found:

This is one of the clearest risk-reduction choices in hormone therapy. For any woman with even modestly elevated VTE risk — obesity, smoking, family history of clot, factor V Leiden, prior pregnancy clot, planned surgery — transdermal delivery is strongly preferred. Many clinicians now default to transdermal for everyone regardless of baseline risk.

Stroke Risk: Oral Estrogen, Age, and Baseline Risk

Stroke risk on HRT follows a similar pattern but is more sensitive to age and cardiovascular baseline. WHI found an increased ischemic stroke risk on oral CEE: roughly 8 extra strokes per 10,000 women-years, concentrated in women over 60 and those with untreated hypertension.

Observational data on transdermal estradiol suggest no meaningful increase in stroke at doses of 50 mcg/day or lower. Higher-dose patches (100 mcg) do appear to carry some excess risk, though the absolute numbers remain small in women under 60.

Practical implications:

Which Progestogen? Micronized Progesterone vs MPA

If you still have a uterus, you need a progestogen alongside systemic estrogen to prevent endometrial hyperplasia and endometrial cancer. The choice of progestogen dramatically changes breast cancer risk.

The French E3N cohort (Fournier et al., 2008) followed 80,377 postmenopausal women for about 8 years and compared breast cancer incidence by HRT regimen:

Longer-term follow-up does show some signal with micronized progesterone after 5+ years of use, so the protection is not absolute — but the difference between bio-identical progesterone and MPA is large and consistent across cohorts. This is why essentially every modern menopause guideline now prefers micronized progesterone (or the progesterone-releasing intrauterine system) over older synthetic progestins for women starting HRT today. See the companion progesterone vs progestins article for dosing details.

Absolute Contraindications — Who Should Not Take HRT

These are the situations where systemic HRT is genuinely off-limits. Vaginal estrogen for GSM is a separate question with a different safety profile — see the GSM article.

Relative contraindications — where a careful conversation with a knowledgeable menopause clinician is needed — include: migraine with aura, uncontrolled hypertension, gallbladder disease, familial hypertriglyceridemia, BRCA1/2 mutation, and dense breast tissue with strong family history.

Personalizing Your Risk: Gail, Family History, BRCA

The population-average numbers above become much more useful when you translate them to your specific risk profile. The two most common tools:

Personal density reports, prior biopsy history showing atypical hyperplasia or lobular carcinoma in situ (LCIS), and first-degree relatives with premenopausal breast cancer are all features that should shift the conversation toward caution or non-hormonal options.

Putting HRT Risk in Everyday Terms

Numbers in isolation are meaningless. Consider what other risks look like per 10,000 women-years:

This is the context the 2002 headlines left out. HRT risk is real and deserves informed consent. It is not categorically different from — and in many configurations is smaller than — risks women routinely accept with a glass of wine, a second helping at dinner, or a commute to work. The Menopause Society's 2022 position statement makes this point in clinical language: for symptomatic women under 60 and within 10 years of menopause, "the benefit-risk ratio is favorable for the treatment of bothersome vasomotor symptoms and for women at elevated risk of bone loss or fracture."

Key Research Papers

PubMed Topic Searches

For further reading, these PubMed searches pull up current peer-reviewed work on HRT risk:

  1. WHI hormone therapy long-term follow-up
  2. Transdermal estradiol and venous thromboembolism
  3. Micronized progesterone and breast cancer risk
  4. HRT timing hypothesis and cardiovascular outcomes
  5. Estrogen-alone and breast cancer in hysterectomy women
  6. Hormone therapy and stroke risk by route
  7. E3N cohort, HRT, and breast cancer
  8. BRCA carriers, HRT, and risk-reducing oophorectomy
  9. The Menopause Society 2022 position statement
  10. Absolute vs relative risk communication in HRT

Connections

Back to Table of Contents